BACKGROUND: Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited syndrome characterized by the development of colorectal cancer (CRC) and other carcinomas. Our aim was to evaluate tumour parameters and survival in HNPCC. METHODS: One hundred and eight Danish HNPCC patients were compared with 870 patients with sporadic colorectal cancer. RESULTS: The median age at CRC diagnosis was 41 years in the HNPCC group. HNPCC patients had significantly more carcinomas located to the right colon (68% against 49% in controls), more synchromous tumours (7% versus 1%), more metachronous CRC after 10 years (29% versus 5%), more localized carcinomas (62% versus 39%), and significantly higher crude cumulative 5-year survival (56% versus 30%). CONCLUSIONS: CRC in HNPCC behaves differently compared to sporadic cases concerning age of onset, frequency of multiple lesions, and location. The metastatic tendency is less than in sporadic CRC and the survival is better.
BACKGROUND: Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited syndrome characterized by the development of colorectal cancer (CRC) and other carcinomas. Our aim was to evaluate tumour parameters and survival in HNPCC. METHODS: One hundred and eight Danish HNPCC patients were compared with 870 patients with sporadic colorectal cancer. RESULTS: The median age at CRC diagnosis was 41 years in the HNPCC group. HNPCC patients had significantly more carcinomas located to the right colon (68% against 49% in controls), more synchromous tumours (7% versus 1%), more metachronous CRC after 10 years (29% versus 5%), more localized carcinomas (62% versus 39%), and significantly higher crude cumulative 5-year survival (56% versus 30%). CONCLUSIONS: CRC in HNPCC behaves differently compared to sporadic cases concerning age of onset, frequency of multiple lesions, and location. The metastatic tendency is less than in sporadic CRC and the survival is better.
Authors: Th E M Crijnen; M L G Janssen-Heijnen; H Gelderblom; J Morreau; M A Nooij; G G Kenter; H F A Vasen Journal: Fam Cancer Date: 2005 Impact factor: 2.375
Authors: Andrew T Schlussel; Ronald A Gagliano; Susan Seto-Donlon; Faye Eggerding; Timothy Donlon; Jeffrey Berenberg; Henry T Lynch Journal: J Gastrointest Oncol Date: 2014-10
Authors: Maartje Nielsen; Liza N van Steenbergen; Natalie Jones; Stefanie Vogt; Hans F A Vasen; Hans Morreau; Stefan Aretz; Julian R Sampson; Olaf M Dekkers; Maryska L G Janssen-Heijnen; Frederik J Hes Journal: J Natl Cancer Inst Date: 2010-11-02 Impact factor: 13.506
Authors: Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin Journal: Mol Oncol Date: 2009-02-21 Impact factor: 6.603
Authors: W Müller; L J Burgart; R Krause-Paulus; S N Thibodeau; M Almeida; T B Edmonston; C R Boland; C Sutter; J R Jass; A Lindblom; J Lubinski; K MacDermot; D S Sanders; H Morreau; A Müller; C Oliani; T Orntoft; M Ponz De Leon; C Rosty; M Rodriguez-Bigas; J Rüschoff; A Ruszkiewicz; J Sabourin; R Salovaara; G Möslein Journal: Fam Cancer Date: 2001 Impact factor: 2.375
Authors: T Fujiwara; J M Stolker; T Watanabe; A Rashid; P Longo; J R Eshleman; S Booker; H T Lynch; J R Jass; J S Green; H Kim; J Jen; B Vogelstein; S R Hamilton Journal: Am J Pathol Date: 1998-10 Impact factor: 4.307
Authors: Alexis L Norris; Nicholas J Roberts; Siân Jones; Sarah J Wheelan; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Alison P Klein; James R Eshleman Journal: Fam Cancer Date: 2015-03 Impact factor: 2.375